Studies from University of Khartoum Have Provided New Data on Visceral Leishmaniasis (LEISH2b - A phase 2b study to assess the safety, efficacy, and immunogenicity of the Leishmania vaccine ChAd63-KH in post-kala azar dermal leishmaniasis...).

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Abstract:
      If therapeutic benefit of ChAd63-KH can be shown in PKDL further evaluation of the vaccine in other forms of leishmaniasis should be considered. Keywords: Biological Products; Drugs and Therapies; Euglenozoa Infections; Health and Medicine; Human Parasites; Immunization; Leishmaniasis; Parasitic Diseases and Conditions; Parasitic Skin Diseases and Conditions; Placebos; Protozoan Infections; Protozoan Parasites; Skin and Connective Tissue Diseases and Conditions; Vaccines; Visceral Leishmaniasis EN Biological Products Drugs and Therapies Euglenozoa Infections Health and Medicine Human Parasites Immunization Leishmaniasis Parasitic Diseases and Conditions Parasitic Skin Diseases and Conditions Placebos Protozoan Infections Protozoan Parasites Skin and Connective Tissue Diseases and Conditions Vaccines Visceral Leishmaniasis 147 147 1 06/12/23 20230612 NES 230612 2023 JUN 12 (NewsRx) -- By a News Reporter-Staff News Editor at Vaccine Weekly -- Research findings on visceral leishmaniasis are discussed in a new report. [Extracted from the article]
    • Abstract:
      Copyright of Vaccine Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)